IL10 and urticaria: Additionally, it reduced the urticaria activity score over 7 days (UAS7) (MD −3.29, 95% CI −3.28 to −2.75, p < 0.00001), the dermatology life quality index (DLQI) (MD −2.95, 95% CI −3.21 to −2.69, p < 0.00001), interleukin-10 (IL-10) levels (MD −1.47, 95% CI −2.01 to −0.93, p < 0.00001), adverse event rate (AER) (OR 0.39, 95% CI 0.20 to 0.77, p = 0.007), and recurrence rate (OR 0.29, 95% CI 0.14 to 0.60, p = 0.0008).